Do analysts rate CCM or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, CCM or MGRX?

Concord Medical Services has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.30 -$13.27M N/A N/A Mangoceuticals $460K 12.95 -$20.64M -$1.49 N/A

Do analysts prefer MRAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MRAI or MGRX more profitable?

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Mangoceuticals -4,639.13% -112.00% -104.96%

Do analysts recommend BMGL or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BMGL or MGRX?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 1.21 -$9.50M N/A N/A Mangoceuticals $460K 12.95 -$20.64M -$1.49 N/A

Do analysts rate MGRX or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer MGRX or ACON?

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 159.52%. Given Aclarion's stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MGRX or ACON more profitable?

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mangoceuticals -4,639.13% -112.00% -104.96% Aclarion -10,320.51% -54.41% -51.71%

Mangoceuticals (MGRX) Competitors

$0.35 +0.06 (+19.24%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$0.34 0.00 (-1.15%)

As of 06:11 AM Eastern

Compare

MGRX vs. CCM, MRAI, BMGL, BRTX, and ACON

Should you buy Mangoceuticals stock or one of its competitors? MarketBeat compares Mangoceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mangoceuticals include Concord Medical Services (CCM), Marpai (MRAI), Basel Medical Group (BMGL), Biorestorative Therapies (BRTX), and Aclarion (ACON). These companies are all part of the "healthcare" industry.

How does Mangoceuticals compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are held by institutional investors. 46.5% of Concord Medical Services shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Concord Medical Services has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market.

In the previous week, Concord Medical Services' average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score.

Company	Overall Sentiment
Concord Medical Services	Neutral
Mangoceuticals	Neutral

Concord Medical Services has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Concord Medical Services' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Concord Medical Services has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.30	-$13.27M	N/A	N/A
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A

Summary

Concord Medical Services beats Mangoceuticals on 6 of the 9 factors compared between the two stocks.

How does Mangoceuticals compare to Marpai?

Marpai (NASDAQ:MRAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

49.8% of Marpai shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 46.1% of Marpai shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mangoceuticals has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.49	-$28.75M	-$0.87	N/A
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Marpai has a beta of 4.94, meaning that its stock price is 394% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

In the previous week, Marpai had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Mangoceuticals. Marpai's average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
Mangoceuticals	Neutral

Summary

Marpai beats Mangoceuticals on 8 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Basel Medical Group has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

In the previous week, Basel Medical Group had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for Mangoceuticals. Basel Medical Group's average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score.

Company	Overall Sentiment
Basel Medical Group	Neutral
Mangoceuticals	Neutral

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.21	-$9.50M	N/A	N/A
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A

Summary

Basel Medical Group beats Mangoceuticals on 6 of the 10 factors compared between the two stocks.

How does Mangoceuticals compare to Biorestorative Therapies?

Mangoceuticals (NASDAQ:MGRX) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Mangoceuticals has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Biorestorative Therapies has lower revenue, but higher earnings than Mangoceuticals. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A
Biorestorative Therapies	$360K	27.54	-$14.24M	-$1.07	N/A

Biorestorative Therapies has a net margin of -3,088.27% compared to Mangoceuticals' net margin of -4,639.13%. Mangoceuticals' return on equity of -112.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biorestorative Therapies had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Biorestorative Therapies and 0 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company	Overall Sentiment
Mangoceuticals	Neutral
Biorestorative Therapies	Neutral

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Mangoceuticals and Biorestorative Therapies tied by winning 6 of the 12 factors compared between the two stocks.

How does Mangoceuticals compare to Aclarion?

Mangoceuticals (NASDAQ:MGRX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Aclarion had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.00 equaled Aclarion'saverage media sentiment score.

Company	Overall Sentiment
Mangoceuticals	Neutral
Aclarion	Neutral

Mangoceuticals has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 159.52%. Given Aclarion's stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Aclarion	-10,320.51%	-54.41%	-51.71%

Aclarion has lower revenue, but higher earnings than Mangoceuticals. Aclarion is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A
Aclarion	$80K	88.87	-$7.23M	-$9.03	N/A

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aclarion beats Mangoceuticals on 8 of the 15 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5M	$2.96B	$6.44B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-0.23	18.43	24.66	23.99
Price / Sales	12.95	326.39	528.55	106.76
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	0.37	4.11	10.83	6.50
Net Income	-$20.64M	$64.45M	$3.56B	$336.88M
7 Day Performance	4.49%	1.41%	0.93%	-0.16%
1 Month Performance	-23.06%	1.04%	0.36%	0.76%
1 Year Performance	-82.82%	23.88%	29.66%	28.49%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	0.915 of 5 stars	$0.35 +19.2%	N/A	-81.3%	$5M	$460K	N/A	3	High Trading Volume
CCM Concord Medical Services	0.4416 of 5 stars	$4.59 +1.1%	N/A	-21.4%	$19.92M	$65.85M	N/A	970
MRAI Marpai	N/A	$0.55 +6.8%	N/A	-49.1%	$14.12M	$34.87M	N/A	150	Gap Down
BMGL Basel Medical Group	0.7139 of 5 stars	$0.56 -3.7%	N/A	-76.0%	$11.22M	$11.32M	N/A	36	Gap Down
BRTX Biorestorative Therapies	0.4242 of 5 stars	$0.37 -2.7%	N/A	-76.3%	$9.33M	$360K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BMGL, BRTX, and ACON

How does Mangoceuticals compare to Concord Medical Services?

Summary

How does Mangoceuticals compare to Marpai?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Summary

How does Mangoceuticals compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BMGL, BRTX, and ACON

How does Mangoceuticals compare to Concord Medical Services?

Do analysts rate CCM or MGRX?

Do insiders & institutionals have more ownership in CCM or MGRX?

Which has more risk and volatility, CCM or MGRX?

Does the media refer more to CCM or MGRX?

Is CCM or MGRX more profitable?

Which has preferable earnings and valuation, CCM or MGRX?

Summary

How does Mangoceuticals compare to Marpai?

Do insiders & institutionals believe in MRAI or MGRX?

Do analysts prefer MRAI or MGRX?

Which has better valuation and earnings, MRAI or MGRX?

Is MRAI or MGRX more profitable?

Which has more volatility and risk, MRAI or MGRX?

Does the media refer more to MRAI or MGRX?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Do analysts recommend BMGL or MGRX?

Do insiders & institutionals hold more shares of BMGL or MGRX?

Is BMGL or MGRX more profitable?

Which has more risk & volatility, BMGL or MGRX?

Does the media prefer BMGL or MGRX?

Which has stronger earnings and valuation, BMGL or MGRX?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Which has more volatility & risk, MGRX or BRTX?

Which has better earnings and valuation, MGRX or BRTX?

Is MGRX or BRTX more profitable?

Do analysts rate MGRX or BRTX?

Does the media prefer MGRX or BRTX?

Do insiders & institutionals hold more shares of MGRX or BRTX?

Summary

How does Mangoceuticals compare to Aclarion?

Does the media prefer MGRX or ACON?

Which has more risk & volatility, MGRX or ACON?

Do analysts prefer MGRX or ACON?

Is MGRX or ACON more profitable?

Which has preferable valuation & earnings, MGRX or ACON?

Do insiders & institutionals hold more shares of MGRX or ACON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools